AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...

Sanofi and Regeneron Pharmaceuticals drug Dupixent ... is in late-stage clinical development with barzovolimab, an antibody drug designed to bind to the KIT receptor on mast cells.

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

which tested the antibody in 65 HoFH patients already being treated with statins, PCSK9 inhibitors and other drugs like ezetimibe. Adding in Regeneron’s antibody resulted in a 49% drop in ...

37% of the standard care group deteriorated to that point, compared to 30% of those on Regeneron's drug. Previous trials in non-hospitalised COVID-19 patients have shown that the antibody therapy ...